Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated a consistentreduction in cardiovascular and kidney outcomes in several randomized clinicaltrials (RCTs) across a range of clinical settings, including type 2 diabetesmellitus,(2) heart failurewith reduced and preserved ejection fraction,(3-6) acute heartfailure,(7) and chronickidney disease.(8,9) Some of the postulated effects of this drugclass(10) may alsopositively impact multiple deleterious pathways of acute illness and protect againstorgan injury and failure. The gene discussed is SLC5A2; the disease is glycogen storage disease VI.